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Abstract
Introduction Tyrosine kinase (TKI) and checkpoint inhibitors (CI) prolonged overall survival in metastatic renal cell carcinoma
(mRCC). Early prediction of treatment response is highly desirable for the individualization of patient management and im-
provement of therapeutic outcome; however, serum biochemistry is unable to predict therapeutic efficacy. Therefore, we com-
pared 18F-PSMA-1007 PET imaging for response assessment in mRCC patients undergoing TKI or CI therapy compared to CT-
based response assessment as the current imaging reference standard.
Methods 18F-PSMA-1007 PET/CT was performed in mRCC patients prior to initiation of systemic treatment and 8 weeks after
therapy initiation. Treatment response was evaluated separately on 18F-PSMA-PET and CT. Changes on PSMA-PET (SUVmean)
were assessed on a per patient basis using a modified PERCIST scoring system. Complete response (CRPET) was defined as
absence of any uptake in all target lesions on posttreatment PET. Partial response (PRPET) was defined as decrease in summed
SUVmean of > 30%. The appearance of new, PET-positive lesions or an increase in summed SUVmean of > 30% was defined as
progressive disease (PDPET). A change in summed SUVmean of ± 30% defined stable disease (SDPET). RECIST 1.1 criteria were
used for response assessment on CT. Results of radiographic response assessment on PSMA-PET and CT were compared.
Results Overall, 11 mRCC patients undergoing systemic treatment were included. At baseline PSMA-PET1, all mRCC patients
showed at least one PSMA-avid lesion. On follow-up PET2, 3 patients showed CRPET, 3 PRPET, 4 SDPET, and 1 PDPET.
According to RECIST 1.1, 1 patient showed PRCT, 9 SDCT, and 1 PDCT. Overall, concordant classifications were found in only
2 cases (2 SDCT+ PET). Patients with CRPET on PET were classified as 3 SDCT on CT using RECIST 1.1. By contrast, the patient
classified as PRCT on CT showed PSMA uptake without major changes during therapy (SDPET). However, among 9 patients with
SDCT on CT, 3 were classified as CRPET, 3 as PRPET, 1 as PDPET, and only 2 as SDPET on PSMA-PET.
Conclusion On PSMA-PET, heterogeneous courses were observed during systemic treatment in mRCC patients with highly
diverging results compared to RECIST 1.1. In the light of missing biomarkers for early response assessment, PSMA-PET might
allow more precise response assessment to systemic treatment, especially in patients classified as SD on CT.
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Introduction
Tyrosine kinase inhibitors (TKIs) and checkpoint inhibitors
(CIs) significantly prolong survival in mRCC patients [1–3].
Early prediction of treatment response is highly desirable for
individualization of patient management and improvement of
outcome. However, established predictive biomarkers for re-
sponse assessment are lacking [4, 5]. Currently, criteria-based
reporting for response assessment relies on morphological im-
aging criteria such as RECIST 1.1. Unlike most other malig-
nancies, the application of 18F-FDG PET/CT in RCC is lim-
ited by its low FDG-avidity [6]. Although preliminary data
have indicated a potential role of 18F-FDG PET/CT for treat-
ment monitoring of nivolumab in RCC patients [7], discordant
published data lead to a missing recommendation in current
guidelines [8]. PSMA is increasingly recognized in prostate
cancer imaging [9]. Moreover, PSMA is highly expressed on
the cell surface of the tumor microvasculature of several solid
tumors [10, 11]. Initial data showed promising results for
PSMA-targeted PET imaging in mRCC and might improve
diagnostic accuracy [10, 12–15].
We hypothesized that PSMA expression as a tumoral fea-
ture of RCC changes under TKI or CIs therapy and that 18F-
PSMA-1007 PET provides pathophysiological information
beyond morphological extent on CT. We therefore compared
18F-PSMA-1007 PET using modified PERCIST criteria to CT
response based on RECIST 1.1 in mRCC patients undergoing
TKI or CI therapy.
Methods
Inclusion criteria
This analysis was approved by the institutional ethics commit-
tee of the LMUMunich (IRB# 20-315). Criteria for inclusion
were (1) histologically provenmRCC, (2) therapy with TKI or
CI, (3) 18F-PSMA-1007 PET/CT prior to therapy with TKI or
CI, and (4) follow-up 18F-PSMA-1007 PET/CT 8 weeks after
therapy initiation.
Radiopharmaceutical and imaging protocol
A median activity of 246 MBq (range 217–268 MBq) 18F-
PSMA-1007 was injected intravenously in line with previous-
ly reported radiosynthesis and administration procedures [16].
Additionally, the patients were premedicated with furosemide
(20 mg) if no contraindication was given [17]. The radiophar-
maceutical was used on an individual patient basis according
to German Pharmaceuticals Act §13(2b). PET was performed
from the skull base to the mid-thigh using a Biograph mCT
scanner or a Biograph 64 PET/CT scanner (Siemens
Healthineers Erlangen, Germany) 60 min after tracer
injection. PET/CT included a diagnostic, contrast-enhanced
CT scan in the portal–venous phase (Imeron 350; 1.5 ml/kg
body weight; Bracco Imaging, Milano, Italy). PET was ac-
quired with 2.5 min per bed position and reconstructed itera-
tively using TrueX (three iterations, 21 subsets) with Gaussian
postreconstruction smoothing (2 mm full-width at half-
maximum).
Radiographic therapy response assessment
Radiographic treatment response was separately assessed on
18F-PSMA-1007 PET and CT datasets. For 18F-PSMA-1007
PET analysis, images were analyzed independently by two
experienced nuclear medicine physicians (MU, HI) on a ded-
icated workstation (Hermes Hybrid 3D Viewer, Hermes
Medical Solutions, Stockholm, Sweden).
18F-PSMA-1007 PET Transaxial PET slices were used for im-
age analysis as described previously [18]. Five organ systems
were included per patient comprising lymph nodes, bone, af-
fected kidney/kidney bed, and other visceral metastatic sites.
Any focal uptake of 18F-PSMA-1007 higher than the sur-
rounding background not associated with physiological up-
take was considered suspicious for malignancy. For each or-
gan system, the two lesions with the highest 18F-PSMA-1007
uptake were analyzed on PET1 (PET1 = PET prior to therapy
initiation). For quantitative analysis, the slice with the maxi-
mum 18F-PSMA-1007 was identified using an isocontour vol-
ume of interest (VOI) including all voxels above 99% of the
maximum covering the whole lesion volume. In a second step,
a spherical VOI with a diameter of 1.5 cm was placed over the
tumor lesion centering in the slice with the maximum 18F-
PSMA-1007 uptake, and the mean standardized uptake vol-
ume (SUVmean) was noted. PET2 (PET2 = PET 8 weeks after
initiation) findings were compared to PET1.
Posttreatment changes were interpreted according to mod-
ified PET Response Criteria in Solid tumors (PERCIST) 1.0
[18]. The absence of any PSMA-uptake on PET2 was defined
as molecular complete response (CRPET). A decrease in
summed SUVmean of ≥ 30% was considered PRPET. The ap-
pearance of new PET-positive lesions on PET2 or an increase
in summed SUVmean of ≥ 30% was considered progressive
disease (PDPET). An intermediate change in summed
SUVmean between − 30 and + 30% without new target lesions
was considered stable disease (SDPET).
CT (RECIST 1.1) For evaluation of CT datasets, response as-
sessment was performed by two experienced radiologists
(WGK, CB) according to RECIST 1.1 using a dedicated soft-
ware (mint lesion™, version 3.0.1, Mint Medical GmbH,
Dossenheim, Germany) [18, 19]. Target and nontarget lesions
were defined and measured in baseline CT prior to therapy
initiation (CT1). In the follow-up CT examination 8 weeks
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after initiation, target lesions were located and manually mea-
sured (CT2). Disappearance of all lesions was considered
complete response (CRCT); a decrease in summed diameters
of ≥ 30% was defined as partial response (PRCT). The appear-
ance of a new target lesion on CT2 or an increase in the
summed diameters of ≥ 20% with an absolute increase of at
least 5 mm was defined as progressive disease (PDCT). An
intermediate change in summed diameter between − 30%
and + 20% without appearance of a new target lesion was
considered stable disease (SDCT).
Statistical analysis
Statistical analyses were performed with IBM SPSS®
Statistics (version 25, IBM Corp., Armonk, NY).
Descriptive statistics are displayed as median (range) or mean
± standard deviation (SD). Relative changes during therapy
are displayed as percentage differences.
Results
Patients and treatment regimen
ElevenmRCCpatients were included in this analysis (mean age
59.6 years (range 24.4–78.4 years; 8 male/3 female). Patients
underwent 18F-PSMA-1007 PET/CT directly before undergo-
ing therapy with TKI or CI and 8 weeks after therapy initiation.
7/11 (63.6%) patients underwent TKI therapy (2x cabozantinib,
3x sunitinib, 1x axitinib, and 1x levantinib + everolimus), 4/11
(36.4%) patients underwent CI therapy (2x ipilimumab +
nivolumab, 1x nivolumab, and 1x pembrolizumab) using
standard dosages without dose reduction during follow-up.
Baseline characteristics are presented in Table 1.
Response assessment
PET-based response assessment Three of 11 (27.2%) patients
showed CRPET with an absence of any PSMA uptake on
PET2. Three of 11 (27.2%) showed PRPET with a decrease
in summed SUVmean of ≥ 30%; in 4/11 patients (36.4%), an
intermediate change in summed SUVmean between − 30% and
+ 30% without appearance of a new target lesion (SDPET) was
seen. One of 11 patients (9.1%) presented with a new, PET-
positive target lesion and was defined as PDPET (Fig. 1).
CT-based response assessmentWhen analyzing the CT-based
response assessment using RECIST 1.1, 1/11 (9.1%) patient
showed PRCT with a decrease in summed diameters of ≥ 30%
(− 35.5%), 9/11 (81.8%) of the patients showed SDCT with an
intermediate change in summed diameter between − 30% and
+ 20% without appearance of any new target lesion, and 1/11
(9.1%) patients had PDCT with an increase in the summed
diameters of ≥ 20%with an absolute increase of at least 5 mm.
Concordance of PET- and CT-based response assessment
Overall, concordant results between PET and CT response
assessments could only be obtained in 2/11 (18.2%) patients,
presenting with SD both on PET and CT (2 SDCT+ PET). Three
patients with CRPET were classified as SDCT on CT, whereas
no patient showed CRCT.
By contrast, 1 patient classified as PRCT on CT showed
PSMA uptake without major changes during therapy
(SDPET). However, among 9 patients with SDCT on CT, 3
Table 1 Baseline characteristics and comparison between radiographic response on 18F-PSMA-1007 and CT
Patient Age Sex Histology Tumor localization° Therapy Δ SUVmean (%) Response on PET Δ RECIST (%) Response on CT
1 48.0 F ccRCC LN, VO Cabozantinib n.e. CR − 13.2% SD
2 77.1 F ccRCC K, LN, VO, B Ipilimumab
Nivolumab
− 12.2% PD* − 29.1% SD
3 74.8 M ccRCC K, LN, VO, B Levantinib
Everolimus
− 28.7% SD − 7.2% SD
4 70.5 M pRCC K, LN, VO, B Sunitinib − 44.7% PR − 1.5% SD
5 52.9 F ccRCC VO Cabozantinib n.e. CR 1.8% SD
6 70.8 M ccRCC VO, LN, B Sunitinib − 68.8% PR − 18.5% SD
7 44.9 M ccRCC VO Axitinib n.e. CR − 26.2% SD
8 24.4 M pRCC K, LN, VO Nivolumab − 9.9% SD 24.8% PD
9 42.8 M uRCC K, LN, VO Ipilimumab
Nivolumab
− 14.2% SD − 35.5% PR
10 73.7 M ccRCC K, VO, B Pembrolizumab − 35.9% PR − 18.3% SD
11 78.4 M ccRCC K, VO Sunitinib − 28.1% SD − 18.9% SD
°As defined on 18 F-PSMA-1007. * PD because of new lesions on PET2. f female, mmale, ccRCC clear cell renal cell carcinoma, pRCC papillary renal
cell carcinoma, uRCC undifferentiated renal cell carcinoma, K kidney, LN lymph nodes, VO visceral organs, B bone, n.e. not evaluable, PD progressive
disease, PR partial response, SD stable disease
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were classified as CRPET, 3 as PRPET, 1 as PDPET, and only 2
as SDPET on PSMA-PET. Concordance between radiographic
responses on PET and CT are presented in Table 2.
Discussion
Our data demonstrate a change of PSMA-PET expression dur-
ing systemic therapy of mRCC in the majority of patients; even
a complete remission of PSMA-expression was observed in 3/
11 patients (27.2%) despite remaining tumor mass with SD on
CT (Fig. 2). Interestingly, the evaluated PET response assess-
ment using PERCIST criteria showed vast discrepancies to
morphological response assessment using RECIST 1.1. Only
2/11 patients comprised a concordant finding on PET and CT,
whereas 9/11 patients (81.8%) showed in parts highly diverging
classifications on PSMA-PET and CT. 6/11 patients (54.5%)
showed CR or PR on PET and SD using RECIST 1.1. This
result suggests that 18F-PSMA-1007 PETmay be able to assess
treatment response on a molecular level earlier than morpho-
logical changes on standard imaging (Fig. 2) with potential
adjustments of the treatment regimen. These findings underline
current data, which could show that PSMA-PET is advanta-
geous over standard imaging with CT alone in mRCC, partic-
ularly for the identification of small lesions such as lymph
nodes [14]. This additional pathophysiological information be-
yond CT morphology could also lead to a decision of continu-
ing or changing current therapy or to de-escalate therapy in
order to reduce drug-related side effects [3].
Conversely, we also observed changes towards progression
on PET with one patient showing PD on PET, but SD on CT.
Here, new osteoblastic lesions in vertebra T7 and L4 with
focally increased PSMA uptake (Fig. 1) were identified.
According to RECIST 1.1, osteoblastic metastases are non-
measurable lesions, as they can be seen as a potential sign of
treatment response, when changing from lytic to blastic [20].
Therefore, a distinction of vital bone metastases and bone
metastases with therapy response remains highly challenging
using morphological imaging with CT [21, 22]. Here, PSMA-
PET could potentially add relevant clinical information with
regard to the response assessment of osseous lesions (Fig. 1).
Also, the scenario of PD on CT, but SD on PET could be
observed in the current cohort. I t is known that
pseudoprogression can occur in patients undergoing immuno-
therapy [23] leading to an early enlargement of tumor manifes-
tations as part of the treatment effect during the early phases
followed by a subsequent shrinkage of tumor lesions [24].
Using RECIST 1.1, this phenomenon would directly lead to
the classification of PD. To overcome these limitations of
RECIST 1.1, several modified response criteria were suggested.
For example, using iRECIST, this phenomenon leads to the
Fig. 1 A 77-year-old female patient showed a new osteoblastic lesion on
follow-up CT during therapy with Ipilimumab and Nivolumab.
According to RECIST 1.1, this is not rated as PD. However, a high
PSMA expression could be seen on PET indicating this lesion to be a
vital metastasis rather than an avital osteoblastic reaction to therapy.
Consequently, this was rated PDPET, although the other tumoral lesions
showed stable uptake on PET
Table 2 Concordance between
radiographic response on PET
and CT
Response PET Response CT
Progressive disease Stable disease Partial response Complete response Total
Progressive disease 0 1* 0 0 1
Stable disease 1° 2 1* 0 4
Partial response 0 3° 0 0 3
Complete response 0 3° 0 0 3
Total 1 9 1 0 11
* Better response on CT. °Better response on PET
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classification of immune unconfirmed progressive disease
(iUPD) [25], which would lead to an additional earlier follow-
up CT scan to confirm either true progression or
pseudoprogression during ongoing immunotherapy. In this sce-
nario, 18F-PSMA-1007 PET could contribute in the early identi-
fication of pseudoprogression and real progression in mRCC
patients undergoing immunotherapy.
One major limitation is the small number of patients as well
as the retrospective design of the study. According to Seitz
et al., we adapted the PERCIST 1.0 criteria [18, 26] for defining
the response categories on PSMA-PET. Although this modified
approach has been shown to be feasible for PSMA-PET in
published studies [18], a prospective validation including end-
points such as overall survival is mandatory to further investi-
gate the use of 18F-PSMA-1007 PET for response assessment.
Within this process, exact cut-off values on PSMA-PET for the
accurate prediction of treatment response in terms of overall
survival are yet to be defined. Additionally, new response
criteria for immunotherapy monitoring such as ‘PET/CT
Criteria for early prediction of Response to Immune checkpoint
inhibitor Therapy’ (PECRIT) and ‘PET Response Evaluation
Criteria for Immunotherapy’ (PERCIMT) that link RECIST 1.1
and PERCIST 1.0 were recently introduced [27, 28]; these par-
ticular specifications of response assessment should also be
evaluated in mRCC patients undergoing PSMA-PET/CT and
be correlated with the clinical outcome in order to evaluate the
best predictive factors on PSMA-PET.
Nonetheless, our preliminary results provide support to the
hypothesis that 18F-PSMA-1007 PET and its combination
with CT provides complementary information on a molecular
level for response assessment in mRCC patients undergoing
systemic treatment with TKI or CI.
Conclusion
On PSMA-PET, heterogeneous courses were observed during
systemic treatment in mRCC patients with highly diverging
results compared to RECIST 1.1 in mRCC patients undergo-
ing systemic treatment with TKI or CI. Hence, hybrid imaging
may optimize response assessment of mRCC patients and
influence patient management. In the light of missing bio-
markers for early response assessment, PSMA-PET might al-
low more precise response assessment to systemic treatment,
especially in those patients classified as stable disease on CT.
Data in correlation with clinical outcome parameters are
underway.
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